On the evening of October 9th, Yiling pharmaceutical company announced that the application for the registration of the new medicine “Lianhuaqingke Tablet” submitted by the company and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. has been officially accepted by the National Medical Products Administration.

Lianhua Qingke Tablet is another innovative Chinese medicine developed by Yiling pharmaceutical company for acute tracheal-bronchitis of common respiratory diseases after Lianhua Qinglan Capsules/granules. Its efficacy is to relieve phlegm,cough,chest tightness and other diseases.

In December 2015, Lianhua Qinglan Capsule was admitted to the second phase of the US FDA clinical research, becoming the first Chinese medicine to enter the US FDA clinical research to treat cold and anti-flu. Lianhua Qinglan Granules and Lianhua Qinglan Capsule ranked 5th and 12th respectively in the sales revenue of 2018 Chinese patent medicine cold medicines, with market shares of 1.82% and 0.95% respectively.

According to the laws and regulations related to national medicine registration, lianhua qingke tablet will be transferred to the medicine evaluation center of National Medical Products Administration for technical evaluation, on-site inspection, sampling inspection and a series of links after receiving the registration application from NMPA.Yiling pharmaceutical company said that the completion time and approval result are uncertain, and the acceptance of registration of this product will not affect the company's recent performance.

Source：http://www.bjnews.com.cn/feature/2019/10/09/634019.html

Time：2019.10.09